Currently active ACTs
| Type of ACT . | Setting in which tested . |
|---|---|
| Activated MILs | After ASCT |
| CAR T cells anti–B-cell maturation antigen | RRMM |
| CAR T cells anti-NKG2D ligands | RRMM |
| CAR T cells anti-CD138 | RRMM |
| CAR T cells anti–κ light chain | RRMM |
| NY-ESO-1– and LAGE-specific TCR-modified T cells | RRMM |
| T cells selected for NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX specificity | Active myeloma after first line |
| Expanded haploidentical NK cells | After ASCT |
| NK cells from donor | After allo-SCT |
| Type of ACT . | Setting in which tested . |
|---|---|
| Activated MILs | After ASCT |
| CAR T cells anti–B-cell maturation antigen | RRMM |
| CAR T cells anti-NKG2D ligands | RRMM |
| CAR T cells anti-CD138 | RRMM |
| CAR T cells anti–κ light chain | RRMM |
| NY-ESO-1– and LAGE-specific TCR-modified T cells | RRMM |
| T cells selected for NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX specificity | Active myeloma after first line |
| Expanded haploidentical NK cells | After ASCT |
| NK cells from donor | After allo-SCT |